|
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases. One development candidate is TELINTRA® (TLK199) which is currently in Phase 2 clinical development for myelodysplastic syndrome, and severe chronic idiopathic neutropenia. TELINTRA® is also being evaluated for the treatment of additional blood disorders. Another product candidate, TELCYTA® (TLK286), is a cancer cell-activated chemotherapeutic that has shown clinical activity in Phase 2 and Phase 3 clinical trials in advanced ovarian cancer, non-small cell lung cancer, colon cancer and breast cancer. These product candidates, and the other candidates in our pipeline, were discovered using our proprietary technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
 12th Annual Bio CEO & Investor Conference
February 9, 2010
3:00 pm ET (12 noon PT)
Click here for the webcast.
2008 Annual Report
2009 Proxy Statement
February 1, 2010
Telik Announces Presentation and Webcast at 12th Annual Bio CEO & Investor Conference
January 25, 2010
Telik Announces INITIATION of Phase 1 clinical Study of Ezatiostat Hydrochloride (TELINTRA®, TLK199) TABLETS in Combination with lenalidomide (Revlimid®) in patients with MyeLodysplastic Syndrome (MDS)
|
